Skip to main content Accessibility help

Monoamine Oxidase Inhibitors: Rehabilitation from Recent Research?

  • David Nutt (a1) and Paul Glue (a1)


For a long time, monoamine oxidase inhibitors (MAOIs) have been the Cinderella drugs of psycho-pharmacy. Although they were introduced just before the tricyclic antidepressants (TCAs), they rapidly became second-line treatments. Several factors contributed to this, in particular the dietary restrictions, the scattered reports of death from overdose and/or toxic interactions, and the unfavourable reports on the efficacy of phenelzine in depression from, among others, the Medical Research Council trial (1965). For a number of years afterwards, prescription of these drugs was limited to a few enthusiasts. More recently, however, their popularity has increased owing firstly to a re-evaluation of their effectiveness in tricyclic-resistant depression and in anxiety disorders, and secondly to growing awareness of the exaggerated claims made about their dangerousness (Pare, 1985).


Corresponding author



Hide All
American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) (DSM-III-R). Washington, DC: APA.
Ask, A. L., Fagervall, I., Jonze, M., et al (1984) Effects of acute and repeated administration of amiflamine on monoamine oxidase inhibition in the rat. Biochemical Pharmacology, 33, 28392847.
Baldessarini, R. J. (1984) Treatment of depression by altering monoamine metabolism: precursors and metabolic inhibitors. Psychopharmacology Bulletin, 20, 224239.
Beaumont, C. (1973) Drug interactions with clomipramine (Anafranil). Journal of International Medical Research, 1, 480484.
Bieck, P. R. & Antonin, K. H. (1988) Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors. Psychopharmacology (Berlin) (suppl.), 31-TU 18.03.
Blackwell, B. (1963) Hypertensive crisis due to monoamine oxidase inhibitors. Lancet, ii, 849851.
Blier, P. & de Montigny, C. (1987) Antidepressant monoamine oxidase inhibitors enhance serotonin but not norepinephrine neurotransmission. In Clinical Pharmacology in Psychiatry (eds Dahl, S. G., Gram, L. F., Paul, S. M. & Potter, W. Z.), pp. 127134. Berlin: Springer-Verlag.
Buiges, J. & Vallejo, J. (1987) Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks. Journal of Clinical Psychiatry, 48, 5559.
Charney, D. S. & Redmond, D. E. (1983) Neurobiological mechanisms in human anxiety. Neuropharmacology, 22, 15311536.
Charney, D. S. & Heninger, G. R. (1986) Abnormal regulation of noradrenergic function in panic disorders. American Journal of Psychiatry, 43, 10421054.
Coppen, A., Shaw, D. M. & Farrell, J. P. (1963) Potentiation of the antidepressive effect of a monoamine oxidase inhibitor by tryptophan. Lancet, i, 7981.
Davidson, J. & Raft, D. (1985) Monoamine oxidase inhibitors in patients with chronic pain. Archives General Psychiatry, 42, 635636.
Dilsaver, S. C. (1988) Monoamine oxidase inhibitor withdrawal phenomena: symptoms and pathophysiology. Acta Psychiatrica Scandinavica, 78, 17.
Graham, P. M. & Ilett, K. F. (1988) Danger of MAOI therapy after fluoxetine withdrawal. Lancet, ii, 12551256.
Hauger, R. L., Scheinin, M., Siever, L. J., et al (1988) Dissociation of norepinephrine turnover from alpha-2 responses after clorgyline. Clinical Pharmacology and Therapeutics, 43, 3238.
Jenike, M. A., Surman, O. S., Cassem, N. H., et al (1983) Monoamine oxidase inhibitors in obsessive-compulsive disorder. Journal of Clinical Psychiatry, 44, 131132.
Kelly, D., Guirguis, W., Frommer, E., et al (1970) Treatment of phobic states with antidepressants. British Journal of Psychiatry, 116, 387398.
Kennedy, S. H., Piran, N. & Garfinkel, P. E. (1985) Monoamine oxidase inhibitor therapy for anorexia nervosa and bulimia: a preliminary trial of isocarboxazid. Journal of Clinical Psychopharmacology, 5, 279285.
King, A. (1962) Phenelzine treatment of Roth's calamity syndrome. Medical Journal of Australia, 23, 879883.
Korn, A., Gasic, S., Jung, M., et al (1984) Influence of moclobemide (RO 11–1163) on the peripheral adrenergic system: interaction with tyramine and tricyclic antidepressants. In Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors (eds Tipton, K. F., Dostert, P. & Benedetti, M. S.), pp. 487496. London: Academic Press.
Larsen, J. K., Holm, P. & Mikkelsen, P. L. (1984) Moclobemide and clomipramine in the treatment of depression. Acta Psychiatrica Scandinavica, 70, 254260.
Liebowitz, M. R., Quitkin, F. M., Stewart, J. W., et al (1985) Effect of panic attacks on the treatment of atypical depressives. Psychopharmacology Bulletin, 21, 558561.
Liebowitz, M. R., Fyer, A. J., Gorman, J. M., et al (1986) Phenelzine in social phobia. Journal of Clinical Psychopharmacology, 6, 9398.
Liebowitz, M. R., Quitkin, F. M., Stewart, J. W., et al (1988) Antidepressant specificity in atypical depression. Archives of General Psychiatry, 45, 129137.
Lipsedge, M. S., Hajioff, J., Huggins, P., et al (1973) The management of severe agoraphobia: a comparison of iproniazid and systematic desensitisation. Psychopharmacologica (Berlin), 32, 6780.
Lydiard, R. B. & Ballenger, J. C. (1987) Antidepressants in panic disorder and agoraphobia. Journal of Affective Disorders, 13, 153168.
Marks, I. M. (1985) Behavioural treatment of social phobia. Psychopharmacology Bulletin, 21, 615618.
Marley, E. & Wozniak, K. M. (1983) Clinical and experimental aspects of interactions between amine oxidase inhibitors and amine reuptake inhibitors. Psychological Medicine, 13, 735749.
McGrath, P. J., Quitkin, F. M., Harrison, W. M., et al (1984) Treatment of melancholia with tranylcypromine. American Journal of Psychiatry, 141, 288289.
Medical Research Council (1965) Clinical trial of the treatment of depressive illness. British Medical Journal, i, 881886.
Murphy, D. L., Garrick, N. A., Aulakh, C. S., et al (1984) New contributions from basic science to understanding the effects of monoamine oxidase inhibiting antidepressants. Journal of Clinical Psychiatry, 45, 3743.
Murphy, D. L., Tamarkin, L., Sunderland, T., et al (1986) Human plasma melatonin is elevated during treatment with the monoamine oxidase inhibitors clorgyline and tranylcypromine but not deprenyl. Psychiatry Research, 17, 119127.
Murphy, D. L., Aulakh, C. S., Garrick, N. A., et al (1987) Monoamine oxidase inhibitors as antidepressants: implications for the mechanism of action of antidepressants and the psychobiology of the affective disorders and some related disorders. In Psychopharmacology: The Third Generation of Progress (ed. Meltzer, H. Y.), pp. 545552. New York: Raven Press.
Nelson, J. C. & Byck, R. (1982) Rapid response to lithium in phenelzine non-responders. British Journal of Psychiatry, 141, 8586.
Nies, A. & Robinson, D. S. (1982) Monoamine oxidase inhibitors. In Handbook of Affective Disorders (ed. Paykel, E. S.), pp. 246261. Edinburgh: Churchill Livingstone.
Nutt, D. J. & Cowen, P. J. (1988) Monoamine function in anxiety and depression: information from neuroendocrine challenge tests. Human Psychopharmacology, 2, 211220.
Nutt, D. J. & Glue, P. (1989) Clinical pharmacology of anxiolytics and antidepressants: a psychopharmacological perspective. Pharmacology and Therapeutics (in press).
Palfreyman, M. G., McDonald, I., Zreika, M., et al (1984) The prodrug approach to brain selective MAO inhibition. In Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors (eds Tipton, K. F., Dostert, P. & Benedetti, M. S.), pp. 561562. London: Academic Press.
Pare, C. M. B. (1985) The present status of monoamine oxidase inhibitors. British Journal of Psychiatry, 146, 576584.
Pare, C. M. B., Kline, N., Hallstrom, C., et al (1982) Will amitriptyline prevent the “cheese” reaction of monoamine oxidase inhibitors? Lancet, ii, 183186.
Quitkin, F. M., Rifkin, A. & Klein, D. F. (1979) Monoamine oxidase inhibitors: a review of antidepressant effectiveness. Archives of General Psychiatry, 36, 749760.
Quitkin, F. M., Liebowitz, M. R., Stewart, J. W., et al (1984) 1-Deprenyl in atypical depressives. Archives of General Psychiatry, 36, 777781.
Robinson, D. S., Kayser, A., Corcella, J., et al (1985) Panic attacks in outpatients with depression: response to antidepressant treatment. Psychopharmacology Bulletin, 21, 562567.
Ross, R. J., Scheinin, M., Lesieur, P., et al (1985) The effect of clorgyline on noradrenergic function. Psychopharmacology (Berlin), 85, 227230.
Rudorfer, M. V., Ross, R. J., Linnoila, M., et al (1985) Exaggerated orthostatic responsivity of plasma norepinephrine in depression. Archives of General Psychiatry, 42, 11861192.
Rudorfer, M. V., Linnoila, M. & Potter, W. Z. (1987) Accidental antidepressants: search for specific action. In Clinical Pharmacology in Psychiatry (eds Dahl, S. G., Gram, L. F., Paul, S. M. & Potter, W. Z.), pp. 157166. Berlin: Springer-Verlag.
Sargant, W. (1963) Combining the antidepressant drugs. Lancet, ii, 634635.
Sargant, W. & Dally, P. (1962) Treatment of anxiety states by antidepressant drugs. British Medical Journal, i, 69.
Schachter, M., Marsden, C. D., Parkes, J. D., et al (1980) Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa. Journal of Neurology, Neurosurgery and Psychiatry, 43, 10161021.
Schiwy, W., Delini-Stula, A. & Heath, W. R. (1988) Brofaromine (MAO-A-inhibitor): summary of dose-finding studies in major (“endogenous”) and other (“non-endogenous”) depressions. Psychopharmacology (Berlin) (suppl.), 31-TU 18.04.
Schoerlin, M-P., Mayersohn, M., Korn, A., et al (1987) Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects. Clinical Pharmacology and Therapeutics, 42, 395404.
Sethna, E. R. (1974) A study of refractory cases in depressive illnesses and their response to combined antidepressant treatment. British Journal of Psychiatry, 124, 265272.
Sheehan, D. V., Ballenger, J. C. & Jacobsen, G. (1980) Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Archives of General Psychiatry, 37, 5159.
Singer, T. P. & Salach, J. I. (1981) Suicide inhibitors of central nervous system enzymes. In Essays in Neurochemistry and Neuropharmacology, vol. 5 (eds Youdim, M. B. H., Lovenberg, W., Sharman, D. F. & Lagnado, J.), pp. 131153. Chichester: Wiley.
Spector, S., Hirsh, C. W. & Brodie, B. B. (1963) Association of behavioural effects of pargyline, a non-hydrazine MAO inhibitor with increase in brain norepinephrine. International Journal of Neuropharmacology, 2, 8193.
Sunderland, T., Mueller, E. A., Cohen, R. M., et al (1985) Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacology (Berlin), 86, 432437.
Sunderland, T., Candy, J. & Kelly, D. (1973) A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety. Psychopharmacologica (Berlin), 32, 237254.
Tyrer, P. (1982) Monoamine oxidase inhibitors and amine precursors. In Drugs in Psychiatric Practice (ed. Tyrer, P.), pp. 249279. London: Butterworths.
Walsh, B. T., Stewart, J. W., Roose, S. P., et al (1984) Treatment of bulimia with phenelzine. Archives of General Psychiatry, 41, 11051109.
West, E. D. & Dally, P. (1959) Effects of iproniazid on depressive syndromes. British Medical Journal, i, 14911494.
Youdim, M. B. H. & Finberg, J. P. M. (1985) Monoamine oxidase inhibitor antidepressants. In Psychopharmacology 2, Part 1: Preclinical Psychopharmacology (ed. Grahame-Smith, D. G.), pp. 3570. Amsterdam: Elsevier.
Zametkin, A., Rapoport, J. L., Murphy, D. L., et al (1985) Treatment of hyperactive children with monoamine oxidase inhibitors. Archives of General Psychiatry, 42, 962977.

Monoamine Oxidase Inhibitors: Rehabilitation from Recent Research?

  • David Nutt (a1) and Paul Glue (a1)


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Monoamine Oxidase Inhibitors: Rehabilitation from Recent Research?

  • David Nutt (a1) and Paul Glue (a1)
Submit a response


No eLetters have been published for this article.


Reply to: Submit a response

Your details

Conflicting interests

Do you have any conflicting interests? *